Home › Trials › NCT04381143

Using aspirin to reduce cardiovascular events in dialysis patients

ASPIrin in Reducing Events in Dialysis

Phase 4 Interventional Guangdong Provincial People's Hospital · NCT04381143

This study is testing if taking low-dose aspirin can help reduce heart problems in people with end-stage kidney disease who are on dialysis.

Quick facts

PhasePhase 4
Study typeInterventional
Enrollment9000 (estimated)
Ages18 Years and up
SexAll
SponsorGuangdong Provincial People's Hospital Academic / other
Locations139 sites (Fuzhou, Fujian and 138 other locations)
Trial IDNCT04381143 on ClinicalTrials.gov

What this trial studies

The ASPIRED trial investigates the effects of low-dose aspirin (100 mg daily) on cardiovascular events in patients with end-stage kidney disease (ESKD) undergoing dialysis. This multi-center, double-blind, randomized controlled trial will utilize existing dialysis registries to efficiently recruit participants and collect data. The study aims to determine whether aspirin can safely improve cardiovascular outcomes compared to a placebo in this high-risk population. Participants will be monitored through routine clinic visits over an anticipated duration of five years.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older who are on maintenance dialysis for chronic kidney disease.

Not a fit: Patients requiring antiplatelet agents or anticoagulants, or those with contraindications to aspirin, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new preventive treatment option to reduce cardiovascular complications in dialysis patients.

How similar studies have performed: While aspirin has been effective in reducing cardiovascular events in the general population, this specific application in dialysis patients is novel and lacks prior evidence.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Incident or prevalent adults (≥18 years old) dialysis patients are included in the Dialysis Registry.
* Commenced on dialysis with the expectation of ongoing maintenance dialysis requirement.
* Willing and able to provide informed consent for this study.

Exclusion Criteria:

* Requirement for any form of antiplatelet agent (aspirin, glycoprotein IIb/IIIa inhibitors etc), or oral anticoagulation (warfarin, NOACs), in the view of the treating physician.
* Contraindication to aspirin, in the view of the treating physician.
* Dialysis requirement due to acute kidney injure with expectation of kidney function recovery.
* History of haemorrhagic stroke or intracranial bleed within 12 months of screening.
* Coagulopathy from any cause.
* Unable to provide informed consent.

Where this trial is running

Fuzhou, Fujian and 138 other locations

+89 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions CKD Stage 5DAspirinDialysisEnd Stage Kidney Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.